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Abstract Background: Opioid analgesics can be abused by crushing followed by solu-
bilization and intravenous injection to attain rapid absorption. Morphine
sulfate and naltrexone hydrochloride extended release capsules (EMBEDA,
MS-sNT), indicated for management of chronic, moderate to severe pain,
contain pellets of morphine sulfate with a sequestered naltrexone core. Should
product tampering by crushing occur, the sequestered naltrexone is intended
for release to reduce morphine-induced subjective effects.
Objective: This study compared self-reports of high, euphoria, and drug-
liking effects of intravenous morphine alone versus intravenous morphine
combined with naltrexone in a clinical simulation of intravenous abuse of crushed
MS-sNT.
Methods: This single-center, randomized, double-blind, crossover study char-
acterized subjective effects of naltrexone administered intravenously at the
same ratio to morphine present in MS-sNT. Subjects were male and had used
prescription opioids five or more times within the previous 12 months to get
‘high’ but were not physically dependent on opioids. The primary outcome
was the response to the Drug Effects Questionnaire (DEQ) question #5, ‘‘How
high are you now?’’ (100mm Visual Analog Scale [VAS]). The secondary
outcome was the response to a Cole/Addiction Research Center Inventory
(ARCI) Stimulation-Euphoria modified scale. Additional outcomes included
response to VAS drug liking, the remaining DEQ questions, and pupillometry.
Results: Administration of intravenous naltrexone following intravenous
morphine diminished mean high (29.8 vs 85.2mm), Cole/ARCI Stimulation-
Euphoria (13.7 vs 27.8mm), and drug-liking (38.9 vs 81.4mm) scores (all
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p < 0.0001) compared with intravenous morphine alone. No serious adverse
events occurred as a result of the tested ratio of naltrexone to morphine.
Conclusions: Results in this study population suggest that naltrexone added
to morphine in the 4% ratio withinMS-sNTmitigates the high, euphoria, and
drug liking of morphine alone, potentially reducing the attractiveness for
product tampering. Assessment of the true clinical significance of these
findings will require further study.
Introduction
Opioid analgesics are an important component
of comprehensive management plans for chronic
pain in appropriately selected and monitored
patients. Extended-release opioid formulations
have enabled patients to attain around-the-clock
pain relief with less frequent dosing than with
immediate-release products; however, they are
vulnerable to tampering by abusers wishing to
gain access to the larger supply of opioid within
each dose unit.[1,2] For example, some prescription
opioids can be abused by injection of solubilized
crushed product to achieve the rapid absorption
and high opioid plasma levels associated with a
‘rush’ or ‘high.’[2]
Abuse of prescription drugs, including opioid
analgesics, has increased substantially since the
mid-1990s,[3-8] creating a need for products that
are a less inviting target for abuse.[9-13] Among
US Department of Health and Human Services,
FDA, Center for Drug Evaluation and Research
recommendations is the call for drug manufac-
turers to ‘‘modify opioid painkillers so that they
are more difficult to tamper with and/or combine
them with agents that block the effect of the
opioid if it is dissolved and injected.’’[14-16] Nal-
trexone hydrochloride is an orally available opioid
antagonist that competitively binds to m-opioid
receptors and reduces the euphoric effects of
m-opioid agonists, such asmorphine.[17] Naltrexone,
administered generally at doses of 50–100mg/day
for oral administration or 380mg/month for intra-
muscular administration, is used as an adjunctive
treatment of alcoholism and for blockade of the
effects of opioids.[18,19] Naltrexone is also present in
amuch smaller amount as a sequestered component
in the individual pellets in morphine sulfate and
naltrexone hydrochloride extended release cap-
sules (EMBEDA, MS-sNT, formerly ALO-01).
MS-sNT is indicated for the management of
chronic, moderate to severe pain.[20] The ratio of
morphine sulfate to naltrexone hydrochloride in
MS-sNT is 100 : 4.[20] Thus, a 30mg capsule of
MS-sNT contains 30mg of morphine sulfate and
1.2mg of sequestered naltrexone, an amount
much lower than the aforementioned clinical
doses of naltrexone.
The sequestered core of naltrexone inMS-sNT
is intended for release only upon product tam-
pering (crushing) to reduce morphine-induced
subjective effects.[20] Previous pharmacokinetic
studies had demonstrated that when pellets from
MS-sNT were crushed and taken orally, both the
morphine and the naltrexone were fully bioavail-
able when compared with the equivalent amount
of morphine and naltrexone in solution.[21,22]
Results of an oral abuse liability study in 32 rec-
reational drug users indicated that MS-sNT cap-
sules, taken orally either whole or with liquid after
the pellets were crushed, were significantly less de-
sirable than morphine sulfate solution, as eval-
uated using several subjective measures including
Cole/Addiction Research Center Inventory (ARCI)
Stimulation-Euphoria,[23] drug liking, and sub-
jective monetary value of drug.[21] Overall, 87.5%
of subjects in the oral study experienced some
degree of reduced drug liking after receiving the
crushed MS-sNT compared with morphine sul-
fate solution.[20]
The purpose of the study presented here was to
assess the abuse liability of MS-sNT if the product
were abused intravenously. Since the excipients in
the crushed oral formulation could cause undue
harm if injected intravenously, a clinical simula-
tion was performed. The relative high, euphoric,
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and drug-liking effects of 30mg of intravenous
morphine alone versus 30mg of intravenous
morphine combined with 1.2mg of intravenous
naltrexone (100 : 4 morphine sulfate to naltrex-
one hydrochloride ratio contained in MS-sNT
capsules) were assessed in recreational opioid
users. Results may further aid in characterizing
the abuse liability of MS-sNT and the potential
to reduce desirability for product tampering.
Methods
Participants
Subjects were men aged 18–50 years who had
used prescription opioids to achieve a ‘high’ at
least five times in the last 12 months, but were not
physically opioid dependent. They were recrea-
tional opioid abusers who only used opioids oral-
ly or snorted. The most commonly abused opioids
among the subjects were consistent with national
data[24] and included hydrocodone/acetaminophen,
oxycodone immediate release and extended re-
lease, and morphine. Subjects who used multiple
drugs expressed a preference for opioids. The sub-
jects were recruited from the database of Lifetree
Clinical Research (Salt Lake City, UT, USA) and
were compensated for their time during partic-
ipation in the study.
Subjects were in generally good health as as-
sessed by medical history and physical examina-
tion, laboratory tests, and ECG, and had negative
urine drug screens for amphetamines, barbitu-
rates, benzodiazepines, cocaine, and opioids upon
presentation for admission to the clinic. Subjects
with a history of significant neurologic, hepatic,
renal, endocrine, cardiovascular, gastrointestinal,
pulmonary, or metabolic disease were excluded, as
were those currently in treatment for substance
abuse or who had completed a substance abuse
program within the previous 90 days.
Subjects could not have used, or have intended
to use, any prescription or over-the-counter (OTC)
medications that could interfere with the evaluation
of medication during the study. Prescription medi-
cations could not have been used within 14 days of
dosing and OTC medications could not have been
used within 48 hours of dosing. Subjects could not
ingest alcohol, grapefruit, or grapefruit juice
within 48 hours of dosing or during the study.
Study Design
This single-center, randomized, double-blind,
crossover study included the following three phases:
(i) naloxone challenge; (ii) drug discrimination; and
(iii) treatment. It was conducted in accordance with
the current FDA regulations, International Con-
ference on Harmonisation guidelines, Good Clin-
ical Practice standards, the Declaration of Helsinki,
and local ethical and legal requirements.[25,26]
Naloxone Challenge Phase
A naloxone challenge was performed on the
day of admission (day 0) to rule out subjects who
were physically dependent on opioids. Subjects
were administered 0.1mg of intravenous nalox-
one; if there were no signs of opioid withdrawal
within 30 seconds, an additional 0.3mg of intra-
venous naloxone was administered and subjects
were observed for withdrawal symptoms for 20min-
utes. Subjects were terminated from the study at
the end of the naloxone challenge phase if they
exhibited signs of opioid withdrawal.
Drug Discrimination Phase
Subjects were randomized to receive one in-
travenous injection of either 10mg of morphine
or placebo on inpatient days 1 and 3 in a double-
blind, crossover fashion, with a 1-day washout on
day 2. Ability to distinguish morphine from placebo
was assessed by the investigator based on subject
responses to a Drug Effects Questionnaire (DEQ;
a nine-item questionnaire with a 100mm visual
analog scale [VAS]; 0 = none, 100 = extreme)[27]
and the Cole/ARCI Stimulation-Euphoria modi-
fied scale, description following in the Study
Endpoints section, at designated time points fol-
lowing each dose.[23,28] At the conclusion of the
drug discrimination phase, the blind was broken.
The investigator determined the subjects who
were able to discriminate between morphine and
placebo and, further, to report a more positive
overall response to morphine versus placebo, using
the response to the aforementioned study end-
point measures, along with clinical judgment.
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Treatment Phase
After a 1-day washout (day 4), subjects entered
the treatment phase (days 5–19) consisting of three
treatment periods. During each treatment period,
subjects received one of the following dose se-
quences: (i) a single 30mg intravenous bolus of
morphine immediately followed by a single intra-
venous bolus of naltrexone placebo; (ii) a single
30mg intravenous bolus of morphine immediately
followed by a single 1.2mg intravenous bolus of
naltrexone; or (iii) a single intravenous bolus of
morphine placebo immediately followed by a
single intravenous bolus of naltrexone placebo.
Dosings were spaced <30 seconds apart. There
was a 6-day outpatient washout between treat-
ments. Subjects were required to have a negative
screen for drugs and alcohol on readmission for
each treatment period.
Study Treatments
Lifetree Clinical Research supplied study treat-
ments as commercially available drug products
for intravenous injection. Subjects, investigators,
and those assessing the outcomes were blinded to
the study drug. Subjects were assigned to treat-
ment in order of enrollment according to a ran-
domization schedule generated by the statistician
and stored in a secured location. The pharmacist
was responsible for completing a master drug
accountability log documenting lot number, date,
and time of drug preparation, and date and time
of delivery to the study center. Treatments were
provided to study centers in prefilled syringes
packaged and labeled with protocol number,
date, and subject initials for the drug discrimina-
tion and treatment phases. Abbott Laboratories
(North Chicago, IL, USA) manufactured the
morphine sulfate, King Pharmaceuticals Inc.
(Bridgewater, NJ, USA) provided the naltrex-
one powder, and Baxter (Deerfield, IL, USA)
manufactured the sodium chloride 0.9% sterile
diluent.
Study Endpoints
Study assessments included pharmacodynamic,
pharmacokinetic, and safety endpoints. On dos-
ing days during the treatment phase, blood
samples for pharmacokinetic measures were
drawn at baseline (before dosing) and at sched-
uled time points (5 minutes to 24 hours post-
dose). Pharmacodynamic outcomes were assessed
immediately following each pharmacokinetic
sampling.
The primary pharmacodynamic endpoint of
this study was assessed by the response to DEQ
question #5, ‘‘How high are you now?’’[27] The
DEQ contained nine items or subscales, each
presented as a 100mm VAS. The DEQ questions
were as follows: (1) ‘‘Do you feel any drug ef-
fects?’’; (2) ‘‘Does the drug have good effects?’’;
(3) ‘‘Does the drug have bad effects?’’; (4) ‘‘Do
you like the drug?’’; (5) ‘‘How high are you
now?’’; (6) ‘‘Does the drug make you feel sick?’’;
(7) ‘‘Do you have nausea?’’; (8) ‘‘Does the drug
make you sleepy?’’; and (9) ‘‘Does the drug make
you dizzy?’’ Subjects were familiar with using the
DEQ and the Cole/ARCI from using these scales
during the drug discrimination phase. The
secondary endpoint was response to the ques-
tions on the Cole/ARCI Stimulation-Euphoria
subscale which consists of 15 statements that sub-
jects rated using a 4-point scale (0–3, a mod-
ification of the 7-point version), where 0 = false,
1 =more false than true, 2 =more true than false,
and 3 = true. The total score is calculated by
adding the individual scores (maximum pos-
sible total score = 45).[23,28] Since the drug-liking
VAS has been used in other studies as a mea-
sure of drug attractiveness,[21] data from DEQ
question #4, ‘‘Do you like the drug?’’ are report-
ed here. Data from the remaining DEQ sub-
scales (#1–3 and #6–9) and pupillometry are also
summarized.
For pupillometry, lighting was controlled
using a light meter to ensure that light was between
3.6 lux and 4.4 lux. Pupil diameter was mea-
sured using a pupil densitometer,[29] with smaller
values (pupillary miosis or constriction) indi-
cating a greater morphine effect. End-tidal car-
bon dioxide levels, measured by noninvasive
capnography, were assessed not as a safety end-
point but as an additional exploratory pharma-
codynamic endpoint and are not included in this
report.
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Analytical Methods
Blood samples (approximately 10mL) for phar-
macokinetic analysis were collected in Vacutainer
tubes containing K2-ethylenediaminetetraacetic
acid for assay of plasma morphine, naltrexone,
and 6-b-naltrexol (the major naltrexone metabo-
lite) concentrations. Immediately after collection,
the tubes were gently inverted to ensure mixing of
the anticoagulant with the blood; samples were
pooled, split into two aliquots, and kept on ice.
Within 45 minutes of collection, samples were
centrifuged at 4C for 10 minutes at 3000 revolu-
tions per minute. Harvested plasma (within 30min-
utes of centrifugation) was stored in an upright
position at -20 – 10C or colder in polypropylene
tubes until analysis. Two complete sets of frozen
samples (a duplicate set for backup) were prepared.
One complete set of samples was carefully packed
in a polystyrene shipper with dry ice, tightly sealed,
and shipped via overnight courier toMDS Pharma
Services (now Celerion) [Lincoln, NE, USA] for
analysis. The duplicate set of samples was stored at
LifetreeClinicalResearch until the sponsor provided
direction for disposal. Concentrations originally
calculated in conventional units were converted
to SI units to allow direct comparison of number
of molecules of morphine versus naltrexone and
6-b-naltrexol. The molecular weights used for the
calculations were morphine monomer 285.34,
naltrexone 341.4, and 6-b-naltrexol 343.42 (e.g.
to convert 50 ng/mL morphine to nmol/L, divide
50ng/mL/molecular weight and multiply by 1000,
which yields 175 nmol/L). Plasma concentrations
of the analytes were measured using validated
liquid chromatography-tandem mass spectrome-
try with the following analytical ranges: 0.876–
175 nmol/L for morphine, 0.0117–1.465 nmol/L
for naltrexone, and 0.0116–4.66 nmol/L for
6-b-naltrexol. Samples with <0.0116 nmol/L
6-b-naltrexol were re-assayed with a more sensi-
tive method (range 0.00146–0.0728 nmol/L).
Safety Outcomes
Safety was evaluated by vital signs, pulse oxim-
etry, physical examinations, ECGs, clinical lab-
oratory tests, and adverse events (AEs). All safety
analyses were based on the double-blind safety
population that included all randomized subjects
who received one or more doses of study med-
ication (intravenous morphine, intravenous nal-
trexone, or intravenous placebo) in the treatment
phase.
Statistical Analysis
Sample size was determined using experience
with studies of similar design that evaluated dif-
ferences between the two active treatments. It was
expected that approximately 76 subjects would be
screened, with 40 participating in the naloxone
challenge, 34 continuing into the drug discrim-
ination phase, and 24 entering the treatment
phase.
For each subject in the pharmacodynamic pop-
ulation (received one or more study treatments in
the double-blind treatment phase and provided
one or more subsequent pharmacodynamic assess-
ments during that phase), the maximum-effect
score within a period (Emax) and time to maximum
effect (TEmax) were identified for each treatment
period. Each pharmacodynamic assessment was
summarized by treatment using descriptive sta-
tistics at each time point. In addition, the mean for
each pharmacodynamic assessment over time was
plotted for each treatment.
WinNonlin version 5.1 (Pharsight Corp.,
Mountain View, CA, USA) was used to calculate
individual subject pharmacodynamic outcomes.
All other analyses and tabulations were per-
formed using SAS version 9.1.3 (SAS Institute
Inc., Cary, NC, USA) on a PC platform. Each
pharmacodynamic assessment was analyzed and
p-values determined using a linear mixed model
(PROC MIXED, SAS) with fixed effects for se-
quence, period, and treatment arm, and a random
effect for subject nested in sequence. Adjustments
for multiple comparisons were made using the
Benjamini and Hochberg[30] method in SAS
PROC MULTITEST. Least squares (LS) means
along with 95% confidence intervals were pro-
vided for each treatment arm and for all pairwise
comparisons between treatment arms. The Emax
was used for pharmacodynamic analyses. The
Emax values were expected to be log-normally
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distributed and were transformed prior to analysis
by taking the natural logarithm. Zero values were
replaced with 0.0001 as an arbitrary small value
because a log transformation is not possible with
zero values. Descriptive statistics as well as esti-
mates of geometric LS means and 95% con-
fidence intervals were calculated.
The pharmacokinetic analyses were based
on all available post-dosing pharmacokinetic
data (n = 28). For each subject, the pharmaco-
kinetic assessments were determined using a non-
compartmental approach for all parameters in
PhAST version 2.3-001 software (1999; Phoenix
Automated Statistics and Tabulation; manufac-
tured by Phoenix International Life Sciences,
located in Montreal, QC, Canada), except con-
centration at time 0 [C0]; C0 was estimated with
ADAPT II Release 4 (1997, Biomedical Simula-
tions Resource, University of Southern California,
Los Angeles, CA, USA). Summary statistics for
plasma concentrations of morphine, naltrexone,
and 6-b-naltrexol were calculated by time and
treatment. For data plotting, plasma concentra-
tion values that were below the limit of quantifi-
cation (BLQ) embedded between two measurable
concentrations were set to missing; however,
BLQ values occurring after the last measurable
plasma concentration were set to zero. For the
purpose of the compartmental pharmacokinetic
analysis (C0 calculations), all BLQ values occur-
ring after the first measurable plasma concen-
tration were set to missing.
Results
Participants
The study was conducted between 20 September
2007 and 21 November 2007. Of the 41 subjects
who were screened, 29 were enrolled. One subject
who failed the drug discrimination phase was
discontinued. All 28 subjects receiving one or
more doses of study drug during the double-blind
treatment phase were included in the pharmaco-
dynamic and safety populations. The evaluable
pharmacodynamic population (completed the
morphine plus naltrexone treatment and one or
more other treatments in the double-blind treat-
ment phase) included 27 subjects. One subject
who had completed the morphine and the place-
bo arms was discontinued for noncompliance
and his data were excluded from the evaluable
pharmacodynamic population. A second subject,
who was included in the evaluable pharmacody-
namic population, was discontinued before com-
pleting placebo treatment due to an AE (a tooth
infection unrelated to study drug).
In the safety population, the age range was
18–36 years (mean– standard deviation: 23.8 –
4.5 years). Twenty-five subjects (89.3%) were
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Fig. 1. Data (mean– standard deviation) are shown for the Drug
Effects Questionnaire (DEQ) question #5, ‘‘How high are you now?’’
after intravenous administration of morphine (n= 28), morphine plus
naltrexone (n=27), and placebo (n= 27) as a function of time (ordinate)
since drug administration in the pharmacodynamic population. Data for
(a) 12 hours and (b) 24 hours post-dose. VAS= visual analog scale.
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Table I. Pharmacodynamic outcomes
Parameter Placebo (n =26) Morphine + naltrexone (n =27) Morphine (n =27)
DEQ #5: ‘‘How high are you now?’’ (primary outcome measure)
Emax (mm)
meana–SD 0.0 – 0.0 29.8 – 26.4b,c 85.2 – 12.9c
range 0–0 0–93.0 55.0–100.0
TEmax (h)
median 0.0 0.1 0.1
range 0–0 0–6.0 0.1–0.8
AUE2 (hmm)
meana–SD 0.0 – 0.0 22.4 – 28.2 129.3 – 37.2
range 0–0 0–115.5 32.3–191.3
AUE8 (hmm)
meana–SD 0.0 – 0.0 41.2 – 40.4 315.0 – 160.5
range 0–0 0–142.5 45.8–621.1
Cole/ARCI Stimulation-Euphoria (secondary outcome measure)
Emax (mm)
meana –SD 1.3 – 3.1 13.7 – 9.5b,c 27.8 – 11.2c
range 0–15.0 0–39.0 4.0–45.0
TEmax (h)
median 0.0 0.1 0.3
range 0–24.0 0–24.0 0.1–2.5
AUE2 (mmunit)
meana–SD -0.2 – 1.0 12.9 – 15.0 43.5 – 23.1
range -4.7 to 0.6 -5.0 to 61.9 0.5–85.5
AUE8 (mmunit)
meana–SD -0.9 – 3.1 31.3 – 33.5 118.3 – 73.6
range -14.7 to 0.1 -21.5 to 113.4 0.5–250.1
DEQ #4: drug liking (additional outcome measure)
Emax (mm)
meana–SD 0.0 – 0.0 38.9 – 30.5b,c 81.4 – 17.1c
range 0–0 0–100 37.0–100
TEmax (h)
median 0.0 0.1 0.3
range 0–0 0–8.0 0.1–1.0
AUE2 (mmunit)
meana–SD 0.0 – 0.0 32.7 – 34.8 130.6 – 41.1
range 0–0 0–138.6 33.7–195.8
AUE8 (mmunit)
meana–SD 0.0 – 0.0 68.1 – 78.0 374.4 – 196.4
range 0–0 0–345.3 41.2–795.6
a Arithmetic mean.
b p <0.0001 vs morphine.
c p< 0.0001 vs placebo.
ARCI =Addiction Research Center Inventory; AUEx= area under the effect curve from time 0 to x hours; DEQ =Drug Effects Questionnaire;
Emax =maximum effect; TEmax = time to maximum effect.
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Pharmacodynamic Outcomes
Mean DEQ #5 (‘‘How high are you now?’’)
values over time are illustrated in figure 1. The
median TEmax was 6 minutes (0.1 hour) for the
morphine and morphine plus naltrexone treat-
ments, and 0 minutes for placebo (see table I).
The arithmetic mean (– standard deviation) score
for the Emax was significantly greater for mor-
phine than morphine plus naltrexone or placebo
(85.2– 12.9mm vs 29.8– 26.4mm vs 0.0– 0.0mm,
respectively; p< 0.0001). This difference was sta-
tistically significant across all three treatment
groups as well as between treatment groups in
pairwise comparisons. Mean area under the effect
curve (AUE) was greater when morphine was
administered alone than when coadministered
with naltrexone (see table I). The median differ-
ence in DEQ #5 Emax score between morphine
and morphine plus naltrexone was 62.0mm (range,
7.0–93.0mm). At maximum effect, only 2 of 27
(7.4%) subjects experienced less than a 10-point
difference.
The results for the Cole/ARCI Stimulation-
Euphoria subscale assessments (see table I and
figure 2) reinforce the findings of the primary
pharmacodynamic assessment of ‘high’. Median
TEmax for morphine plus naltrexone was 0.1 hour
and for morphine was 0.3 hours. Arithmetic mean
Emax scores were significantly greater for mor-









































































0 4 8 12
Time post-dose (h)
16 20 24
1 2 3 4 5 6 7 8 9 10 11 12
Fig. 2. Data (mean – standard deviation) are shown for the Cole/
Addiction Research Center Inventory (ARCI) Stimulation-Euphoria
subscale scores after intravenous administration of morphine
(n= 28), morphine plus naltrexone (n = 27), and placebo (n =27) as
a function of time (ordinate) since drug administration in the phar-
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Fig. 3. Data (mean– standard deviation) are shown for the Drug
Effects Questionnaire (DEQ) question #4, ‘‘Do you like the drug?’’ after
intravenous administration of morphine (n= 28), morphine plus nal-
trexone (n=27), and placebo (n= 27) as a function of time (ordinate)
since drug administration in the pharmacodynamic population. Data
for (a) 12 hours and (b) 24 hours post-dose.VAS= visual analog scale.
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(27.8mm vs 13.7mm vs 1.3mm, respectively;
p< 0.0001). Mean AUE was greater when mor-
phine was administered alone than when ad-
ministered with naltrexone (see table I). Overall,
71% of subjects reported a reduction in euphoria
with morphine plus naltrexone compared with
morphine alone.[20]
Arithmetic mean values over time for DEQ
question #4, ‘‘Do you like the drug?’’ are shown
in figure 3. Median TEmax for morphine plus
naltrexone was 0.1 hour and for morphine was
0.3 hours. Arithmetic mean score for Emax for
drug liking was significantly greater for morphine
thanmorphine plus naltrexone or placebo (81.4mm
vs 38.9mm vs 0.0mm, respectively; p < 0.0001)
and mean AUE was greater when morphine was
administered alone than when administered with
naltrexone (see table I).
For each of the remaining seven DEQ ques-
tions, the Emax for morphine was greater than for
morphine plus naltrexone and placebo. Statisti-
cally significant geometric mean differences in
Emax were detected across all three treatments
(p < 0.0001). For the ‘desirable’ (positive subjec-
tive effects) DEQ outcomes of #1 (drug effects),
#2 (feeling good effects), and #4 (liking the drug),
the median TEmax was similar or slightly shorter
for morphine than morphine plus naltrexone.
Median TEmax values for the ‘undesirable’ (neg-
ative subjective effects) DEQ outcomes of #3 (bad
effects), #6 (feeling sick), #7 (having nausea), #8
(feeling sleepy), and #9 (feeling dizzy) were earlier
formorphine plus naltrexone than formorphine.[21]
Pupillometry Analysis
The peak morphine drug effect was observed
when the pupil diameter was smallest (indicative
ofmorphine-induced constriction).Minimumpupil
diameter is noted as Emin, the baseline for com-
parison when noting increase in pupil size. Fol-
lowing intravenous administration of morphine
alone, the mean Emin (2.4mm) was significantly
reduced relative to placebo (4.4mm) and mor-
phine plus naltrexone (3.4mm) [p < 0.0001 for
both comparisons]. Median time to reach this
minimum pupil diameter (TEmin) after morphine
alone was rapid (0.8 hours) compared with pla-
cebo (3.0 hours) and morphine plus naltrexone
(4.0 hours). The miotic effect was temporally de-
layed relative to morphine alone when morphine
was administered intravenously with naltrexone.
Table II. Exploratory outcome: pupillometry
Parameter Placebo (n =26) Morphine + naltrexone (n =27) Morphine (n =27)
Emin (mm)
meana–SD 4.4 – 0.8 3.4 –0.6b,c 2.4 – 0.3c
range 3–6 2–4 2–3
TEmin (h)
median 3.0 4.0 0.8
range 0–24 0–12 0.1–2.5
AUE2 (hmm)
meana–SD 0.0 – 0.9 -1.3 – 1.5 -5.0 – 1.8
range -2.0 to 1.4 -3.4 to 2.3 -8.1 to -1.4
AUE8 (hmm)
meana–SD 0.3 – 4.8 -8.5 – 6.8 -18.8 – 8.0
range -10.6 to 9.1 -19.1 to 6.4 -32.7 to -4.7
a Arithmetic mean.
b p <0.0001 vs morphine.
c p< 0.0001 vs placebo.
AUEx= area under the effect curve from time 0 to x hours; Emin=minimum pupil diameter (maximum effect); SD = standard deviation;
TEmin= time to minimum pupil diameter (maximum effect).
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Mean AUE from time 0 to 8 hours for miosis was
smaller (-18.8hmmvs -8.5hmm) formorphine
alone relative to morphine plus naltrexone and
placebo (see table II and figure 4).
Pharmacokinetics
Plasma morphine concentration-time profiles
and pharmacokinetic parameters were similar for
intravenous morphine alone compared with
concomitant intravenous naltrexone administra-
tion, including extent of exposure (area under the
plasma drug concentration-time curve) at the
measured time points (see table III and figure 5).
This similarity demonstrated that the coadmin-
istration of naltrexone and morphine had no ap-
parent effect on the morphine pharmacokinetics
when compared with morphine administered alone.
Following single intravenous bolus administrations,
morphine, naltrexone, and 6-b-naltrexol reached
peak concentrations immediately after dosing and
then decreased in a multi-exponential manner (see
figure 5). Pharmacokinetic assessments of mor-




Based on additional exploratory analysis,
figure 6a shows a hysteresis plot of percentage
change in euphoria abatement versus mean plasma
naltrexone concentration using the Cole/ARCI
Stimulation-Euphoria subscale over time. Subjects
who did not experience euphoria (18.5%, 5 of 27)
were not included in the analysis. The plasma nal-
trexone rapidly reached its peak level (21.4 nmol/L)
by 5 minutes and then decreased. This is related to
a median 63% abatement of the morphine-induced
euphoria. The naltrexone-induced euphoria abate-
ment continued and reached amaximumof 80% by
30 minutes. Figure 6b shows the increase in pupil
size (relative to that with morphine) plotted against
plasma naltrexone concentration over time. The
mean naltrexone peak plasma level at 5 minutes is
related to a 2mm increase in pupil size showing the
blocking of the morphine-induced pupil constric-
tion. This effect was maintained until 45 minutes
and gradually decreased in relation to the lower
plasma naltrexone levels over time.
Safety
In this study, 21 of 28 (75%) subjects experi-
enced a total of 69 AEs. Nineteen (67.9%) sub-
jects experienced 50 of these AEs when treated
with morphine alone. By contrast, 9 of 27 (33.3%)
subjects experienced 17 AEs during treatment
with morphine plus naltrexone and two (7.4%)
subjects taking placebo reported two events (see
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Fig. 4. Pupillometry data (mean– standard deviation) over time (phar-
macodynamic population). Data for (a) 12 hours and (b) 24 hours
post-dose.
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pruritus, nausea, and vomiting (see table IV). One
subject discontinued because of an AE (tooth
infection). There were no deaths or serious AEs.
No clinically significant abnormal laboratory
values were reported. One subject reported a
moderately severe episode of vasovagal syncope,
which was considered by the investigator to be
unrelated to study drug and resolved sponta-
neously on the day of onset. No study drug-
related changes in vital signs or physical findings
were noted.
Discussion
The goal of this study was to assess the intra-
venous abuse liability of MS-sNT by simulating
the intravenous abuse of the product by recrea-
tional opioid abusers. The relative effects of in-
travenous morphine alone or in combination
with intravenous naltrexone in a 100 : 4 ratio on
high, euphoria, and drug liking were assessed.
For the primary endpoint DEQ #5 (‘‘How
high are you now?’’) maximum effect achieved
with morphine alone was approximately 3-fold
greater than for morphine plus naltrexone. The
maximum effect for placebo was 0.0mm. On the
Cole/ARCI Stimulation-Euphoria subscale, the eu-
phoric effect of morphine alone was approx-
imately twice that of morphine plus naltrexone.
Maximum effect for both treatments was sig-
nificantly different from placebo. The maximum
effect for drug liking of morphine alone was ap-
proximately 2-fold greater than for morphine
plus naltrexone. Results consistently demonstrat-
ed greater subjective effects when morphine was
taken intravenously alone than when it was ad-
ministered with the naltrexone.
The remaining pharmacodynamic analyses
(DEQ #1–3 and #6–9) demonstrated that, in most
instances, the mean maximum values for mor-
phine alone were significantly greater than the
corresponding values for morphine plus naltrex-
one and placebo groups. For each DEQmeasure,
morphine plus naltrexone provided significantly
greater effect compared with placebo, but with
a sufficient dosage of naltrexone to significantly
mitigate the morphine subjective effects. Com-
pared with morphine alone, the subjectively ap-
pealing attributes of the drug (such as feeling
drug effects, feeling good effects, and liking the
drug) occurred more slowly, while the unappeal-
ing attributes became evident more quickly after
the morphine plus naltrexone combination. This
suggests that the presence of naltrexone contri-
buted appreciably to the abatement of morphine
high and euphoria without decreasing the un-
pleasant effects (e.g. nausea, sleepiness) associated
with morphine use.
Table III. Summary of pharmacokinetic assessments
Parameter Morphine alone (n =28) Morphine + naltrexone (n= 26)
plasma morphine plasma morphine plasma naltrexone plasma 6-b-naltrexol
C0 (nmol/L)a 2895 (94.4%) 3235 (92.5%) 32 (77.2%) NA
AUC2 (nmolh/L)a 624 (28.2%) 641 (29.6%) 15 (19.4%) 6 (25.8%)
AUC8 (nmolh/L)a 911 (23.2%) 967 (25.3%) 24 (20.5%) 22 (18.4%)
AUCt (nmolh/L)a 1016 (21.1%) 1104 (23.7%) 25 (21.0%) 42 (18.4%)
AUC¥ (nmolh/L)a 1100 (15.4%) 1167 (25.4%) 25 (21.3%) 58 (18.2%)
t½ (h)
b 9.62 (5.44) 8.32 (3.68) 3.12 (1.0) 13.2 (2.56)
Vss (L)
b 394 (215) 336 (136.4) 299 (59.8) NA
CLt (L/h)b 72.8 (10.7) 69.7 (14.43) 128 (26.5) NA
a Geometric mean (CV%).
b Arithmetic mean (SD).
AUCt =area under the plasma concentration curve at time t, where t is either 12 hours or 24 hours depending on the time of last measureable
concentration; AUC¥ =area under the plasma drug concentration-time curve from time zero to infinity; AUCx= area under the plasma drug
concentration-time curve from 0 to x hours; C0= anticipated initial plasma drug concentration; CLt= total plasma clearance; CV = coefficient of
variation; NA =not available; t½ = terminal half-life; Vss= volume of distribution at steady state.
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An analysis performed subsequent to this study
suggested that differences of 8–10mm in VAS
ratings of ‘high’ indicate clinical significance.[31]
As shown in figure 1 in the current study, the
mean difference in VAS scores for DEQ question
#5, ‘‘How high are you now?’’ observed between
morphine plus naltrexone and morphine alone
remained greater than 10mm from 5 minutes
post-dose through 8 hours post-dose. At max-
imum effect, only 2 of 27 (7.4%) subjects experi-
enced less than a 10-point difference.
In the context of this clinical simulation, the
study treatments were well tolerated. It is likely
that adverse consequences would be much great-
er in cases of parenteral abuse of MS-sNT due to
the presence of excipients such as talc. However,
results of this study should serve as an indication
that, in addition to the potential harm caused by
tampering with and injecting MS-sNT, the de-
sired high would not be attained.
As morphine causes miosis,[29,32,33] pupillo-
metry measurements were introduced as an ob-
jective measure of opioid effect. The geometric
mean Emin was significantly smaller after intra-
venous morphine than after placebo or after
morphine plus naltrexone. Furthermore, the me-
dian TEmin was significantly quicker with mor-
phine alone than for placebo or morphine plus
naltrexone. In addition, a relationship was observ-
ed between plasma naltrexone levels and pupil
dilation over time in the hysteresis plot, showing
an increase in pupil size (relative to morphine
alone) of 2mm for maximum naltrexone plasma
levels after 5 minutes. This finding suggests that
the morphine-induced decrease in pupil diameter
was inhibited by naltrexone. This effect was sus-
tained for 45 minutes and then gradually de-
creased as the plasma naltrexone levels decreased.
The persistence of a smaller pharmacodynamic
effect (continued difference between morphine
and morphine plus naltrexone) over the re-
mainder of the 12-hour period is likely caused by
a dose effect related to receptor binding. The
relatively smaller dose of naltrexone combined
with high hepatic clearance may result in reduced
temporal effect from that of the much higher dose
of morphine. The timing of morphine-induced
effects observed in this study is in agreement with
that from a recently published study in which intra-
venous morphine was administered to intravenous-
experienced recreational opioid users.[34]
A pharmacokinetic-pharmacodynamic relation-
ship was also observed for the plasma naltrexone
levels in relation to the morphine-induced eupho-
ria as measured by the Cole/ARCI Stimulation-
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Fig. 5. Mean (mean – standard error of the mean) plasma concen-
tration-time plots for plasma (a) morphine, (b) naltrexone, and (c) 6-X-
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euphoria abatement and versus change in pupil
diameter hysteresis curves validates the naltrexone
effect on the subjective responses.
Although administered within 30 seconds, it is
possible that the sequential administration of
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Fig. 6. Data are shown for the hysteresis plot of (a) percentage change in euphoria abatement vs naltrexone concentration over time after
administration of intravenous (IV) morphine followed by IV naltrexone (n =22); and (b) increase in pupil size vs naltrexone concentration over
time after administration of IV morphine followed by IV naltrexone (n =27).
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high as the delayed effect of displacement of
morphine from the m-opioid receptors followed
by the administration of naltrexone took place.
If pellets from MS-sNT capsules were crushed,
dissolved, solubilized, and then injected, both mor-
phine and naltrexone would be simultaneously in-
jected. It would have been inappropriate to conduct
such a study with crushed pellets due to the concern
over the presence of excipients such as talc, but fu-
ture studies of this nature could include simulta-
neous administration. Additional studies assessing
bioavailability and subjective responses to admin-
istration of tampered product by routes other than
intravenous or oral (e.g. nasal) are also warranted.
This controlled clinical study was conducted in
opioid-experienced, non-opioid-dependent men
who had not previously used the intravenous
route to abuse their drugs. Selection of the study
population in human drug-abuse liability studies
may impact outcomes and present challenges for
which there are few established standards.[12,35,36]
Guidance from the Center for Drug Evaluation
and Research suggests that subjects in a study
should have experience with drugs with psycho-
active properties similar to those of the study
drug, but do not specify route of administra-
tion.[37] National Advisory Council on Drug Abuse
guidelines state that the ‘‘rationale for exposure
to new drugs, to higher doses, or to new routes of
administration should be clear and compel-
ling.’’[38] For example, one may question whether
the experience of intravenous administration of
an opioid in subjects who had not previously used
this route to abuse opioids might encourage future
opioid abuse by the intravenous route. Abuse
liability studies involving intravenous adminis-
tration of the study drug have been performed
in non-drug-abusing subjects, intravenous-naive
subjects, and intravenous-experienced abus-
ers.[34,36,39,40] A small study reported that cocaine
use patterns did not change after intravenous-
naive subjects participated in a study with inves-
tigational intravenous cocaine administration.[40]
Kaufman, et al.[40] suggested that this outcome
was influenced by the fact that the controlled
clinical setting in which the intravenous drug was
administered during the study was very different
from that typically associated with intravenous
drug abuse. Overall, the findings from this and
other similarly designed trials provide a basis for
establishing abuse liability. However, these re-
sults are centered on a subset of the population of
abusers (i.e. nondependent recreational drug users).
Abuse liability may differ in other subsets of drug
users such as opioid-dependent individuals who,
upon tampering, may be susceptible to naltrexone-
precipitated withdrawal (e.g. patients with chronic
pain whomisuse or abuse opioids, abusers addicted
to opioids, or to new initiates to opioid abuse). A
study is underway to determine the effects of the
quantity of naltrexone in MS-sNT on opioid-
dependent individuals. Future studies are needed
to address the overall impact that MS-sNT and
other formulations designed to reduce attractive-
ness for abuse will have on misuse, abuse, and
diversion in the community.
Table IV. Most frequently reported (one or more) adverse events (AEs) [n (%)]
AE Placebo (n= 27) Morphine +naltrexone (n =27) Morphine (n =28)
Subjects reporting ‡1 AE 2 (7.4) 9 (33.3) 19 (67.9)
Pruritus 0 (0.0) 1 (3.7) 10 (35.7)
Nausea 1 (3.7) 3 (11.1) 9 (32.1)
Vomiting 0 (0.0) 1 (3.7) 7 (25.0)
Headache 0 (0.0) 4 (14.8) 2 (7.1)
Dizziness 0 (0.0) 2 (7.4) 3 (10.7)
Nasal discomfort 0 (0.0) 0 (0.0) 3 (10.7)
Hiccups 0 (0.0) 0 (0.0) 2 (7.1)
Irritability 0 (0.0) 0 (0.0) 2 (7.1)
Dysuria 0 (0.0) 0 (0.0) 3 (10.7)
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Conclusion
Opioids are effective and important in the
treatment of chronic, moderate to severe pain in
appropriately selected patients;[41] however, in the
current climate of increased illicit use of prescrip-
tion opioid analgesics, there is a need to address
the goal of successfully treating pain while mini-
mizing the risks of abuse.[11] MS-sNT capsules
provide analgesia when taken orally as directed
but are designed to release naltrexone if they are
tampered with by crushing. Results of this intra-
venous study suggest that the ratio of naltrexone
to morphine withinMS-sNT capsules is sufficient
to decrease the subjective effects ofmorphine should
MS-sNT pellets be tampered with by crushing
and solubilized and then injected intravenously in
subjects similar to the study population. This
feature may reduce the consequent attractiveness
ofMS-sNT capsules to these abusers. Assessment
of the true clinical significance of these findings
will require further study.
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